ANCC FNP CERTIFICATION EXAM PREP
2026 COMPLETE QUESTIONS AND
VERIFIED DETAILED RATIONALES
GRADED A+
Assessment & Clinical Management
Q1. A 58-year-old male with chronic heart failure with
reduced ejection fraction (HFrEF) presents with
worsening dyspnea and bilateral lower extremity edema.
His current regimen includes lisinopril and metoprolol
succinate. His serum potassium is 4.8 mEq/L and eGFR
is 52 mL/min/1.73m². Which medication addition is best
supported by current guideline-directed medical therapy
(GDMT) to reduce mortality?
• A. Furosemide 40 mg daily
• B. Empagliflozin (SGLT2 inhibitor) 10 mg daily
• C. Amlodipine 5 mg daily
• D. Digoxin 0.125 mg daily
CorreCt Answer: B
rAtionAle: Sodium-glucose cotransporter 2 (SGLT2)
inhibitors are now a foundational "fourth pillar" of
HFrEF management alongside ARNI/ACEi/ARBs, beta-
blockers, and mineralocorticoid receptor antagonists
(MRAs). Large clinical trials have demonstrated that
SGLT2 inhibitors significantly reduce cardiovascular
,mortality and heart failure hospitalizations regardless of
the presence of Type 2 diabetes. Furosemide controls
volume but does not lower mortality; amlodipine can
worsen peripheral edema; and digoxin reduces
hospitalization rates without improving survival.
Q2. A 64-year-old female with a 40 pack-year smoking
history presents with a 4-month history of a chronic,
productive cough and recurrent mild respiratory
exacerbations. Her spirometry demonstrates a post-
bronchodilator FEV1/FVC ratio of 0.62 and an FEV1 of
58% predicted. According to GOLD guidelines, which
initial pharmacotherapy class is most appropriate?
• A. Inhaled corticosteroid (ICS) monotherapy
• B. Oral azithromycin maintenance therapy
• C. Long-acting muscarinic antagonist (LAMA) or long-
acting beta2-agonist (LABA)
• D. High-dose systemic oral corticosteroids daily
CorreCt Answer: C
rAtionAle: The patient meets the diagnostic
threshold for COPD (post-bronchodilator FEV1/FVC <
0.70) and is classified under GOLD Group B due to
persistent daily symptoms without severe hospitalizing
exacerbations. Initial long-term maintenance consists of
a long-acting bronchodilator (either a LAMA or a LABA).
Inhaled corticosteroid (ICS) monotherapy is strictly
avoided in COPD due to lack of efficacy and increased
,pneumonia risk. Azithromycin and systemic steroids are
reserved for refractory or acute exacerbation scenarios.
Q3. A 45-year-old male with type 2 diabetes has an
HbA1c of 8.6% despite maximal metformin therapy and
lifestyle modifications. He has a history of established
atherosclerotic cardiovascular disease (ASCVD) and
stage 3a chronic kidney disease (eGFR 48 mL/min).
Which glucose-lowering agent provides specific
cardiorenal protection in this scenario?
• A. Glipizide
• B. Sitagliptin
• C. Insulin glargine
• D. Dulaglutide (GLP-1 receptor agonist)
CorreCt Answer: D
rAtionAle: ADA guidelines recommend that patients
with Type 2 diabetes and established ASCVD, heart
failure, or chronic kidney disease be prescribed a GLP-1
receptor agonist or an SGLT2 inhibitor with proven
cardiorenal benefit. GLP-1 receptor agonists like
dulaglutide reduce major adverse cardiovascular events
(MACE) and slow macroalbuminuria progression.
Sulfonylureas (glipizide), DPP-4 inhibitors (sitagliptin),
and basal insulin lower glucose but lack these protective
vascular benefits.
Q4. A 72-year-old female presents with a 2-year history
of progressive memory decline, word-finding difficulty,
and getting lost in her own neighborhood. Her physical
, exam is normal except for cognitive impairment on the
Montreal Cognitive Assessment (MoCA). An MRI
demonstrates diffuse cortical atrophy with prominent
hippocampal shrinkage. What is the primary underlying
pathophysiology?
• A. Extracellular beta-amyloid plaques and intracellular
neurofibrillary tau tangles
• B. Alpha-synuclein cytoplasmic inclusions
• C. Focal vascular infarcts of the basal ganglia and cortex
• D. Prion protein conformational changes forming
spongiform encephalopathy
CorreCt Answer: A
rAtionAle: The clinical history and MRI findings are
classic for Alzheimer's disease, the most common cause
of dementia in older adults. The primary
histopathological markers are extracellular plaques
composed of amyloid-beta peptides and intracellular
neurofibrillary tangles containing hyperphosphorylated
tau proteins. Alpha-synuclein inclusions characterize
Lewy body dementia; focal vascular infarcts define
vascular dementia; and prion mutations trigger rapidly
progressive Creutzfeldt-Jakob disease.
Q5. A 30-year-old female presents with recurrent
abdominal pain associated with defecation, alternating
diarrhea and constipation, and bloating for the past 9
months, satisfying Rome IV criteria for Irritable Bowel
Syndrome (IBS). Alarm features like weight loss and
2026 COMPLETE QUESTIONS AND
VERIFIED DETAILED RATIONALES
GRADED A+
Assessment & Clinical Management
Q1. A 58-year-old male with chronic heart failure with
reduced ejection fraction (HFrEF) presents with
worsening dyspnea and bilateral lower extremity edema.
His current regimen includes lisinopril and metoprolol
succinate. His serum potassium is 4.8 mEq/L and eGFR
is 52 mL/min/1.73m². Which medication addition is best
supported by current guideline-directed medical therapy
(GDMT) to reduce mortality?
• A. Furosemide 40 mg daily
• B. Empagliflozin (SGLT2 inhibitor) 10 mg daily
• C. Amlodipine 5 mg daily
• D. Digoxin 0.125 mg daily
CorreCt Answer: B
rAtionAle: Sodium-glucose cotransporter 2 (SGLT2)
inhibitors are now a foundational "fourth pillar" of
HFrEF management alongside ARNI/ACEi/ARBs, beta-
blockers, and mineralocorticoid receptor antagonists
(MRAs). Large clinical trials have demonstrated that
SGLT2 inhibitors significantly reduce cardiovascular
,mortality and heart failure hospitalizations regardless of
the presence of Type 2 diabetes. Furosemide controls
volume but does not lower mortality; amlodipine can
worsen peripheral edema; and digoxin reduces
hospitalization rates without improving survival.
Q2. A 64-year-old female with a 40 pack-year smoking
history presents with a 4-month history of a chronic,
productive cough and recurrent mild respiratory
exacerbations. Her spirometry demonstrates a post-
bronchodilator FEV1/FVC ratio of 0.62 and an FEV1 of
58% predicted. According to GOLD guidelines, which
initial pharmacotherapy class is most appropriate?
• A. Inhaled corticosteroid (ICS) monotherapy
• B. Oral azithromycin maintenance therapy
• C. Long-acting muscarinic antagonist (LAMA) or long-
acting beta2-agonist (LABA)
• D. High-dose systemic oral corticosteroids daily
CorreCt Answer: C
rAtionAle: The patient meets the diagnostic
threshold for COPD (post-bronchodilator FEV1/FVC <
0.70) and is classified under GOLD Group B due to
persistent daily symptoms without severe hospitalizing
exacerbations. Initial long-term maintenance consists of
a long-acting bronchodilator (either a LAMA or a LABA).
Inhaled corticosteroid (ICS) monotherapy is strictly
avoided in COPD due to lack of efficacy and increased
,pneumonia risk. Azithromycin and systemic steroids are
reserved for refractory or acute exacerbation scenarios.
Q3. A 45-year-old male with type 2 diabetes has an
HbA1c of 8.6% despite maximal metformin therapy and
lifestyle modifications. He has a history of established
atherosclerotic cardiovascular disease (ASCVD) and
stage 3a chronic kidney disease (eGFR 48 mL/min).
Which glucose-lowering agent provides specific
cardiorenal protection in this scenario?
• A. Glipizide
• B. Sitagliptin
• C. Insulin glargine
• D. Dulaglutide (GLP-1 receptor agonist)
CorreCt Answer: D
rAtionAle: ADA guidelines recommend that patients
with Type 2 diabetes and established ASCVD, heart
failure, or chronic kidney disease be prescribed a GLP-1
receptor agonist or an SGLT2 inhibitor with proven
cardiorenal benefit. GLP-1 receptor agonists like
dulaglutide reduce major adverse cardiovascular events
(MACE) and slow macroalbuminuria progression.
Sulfonylureas (glipizide), DPP-4 inhibitors (sitagliptin),
and basal insulin lower glucose but lack these protective
vascular benefits.
Q4. A 72-year-old female presents with a 2-year history
of progressive memory decline, word-finding difficulty,
and getting lost in her own neighborhood. Her physical
, exam is normal except for cognitive impairment on the
Montreal Cognitive Assessment (MoCA). An MRI
demonstrates diffuse cortical atrophy with prominent
hippocampal shrinkage. What is the primary underlying
pathophysiology?
• A. Extracellular beta-amyloid plaques and intracellular
neurofibrillary tau tangles
• B. Alpha-synuclein cytoplasmic inclusions
• C. Focal vascular infarcts of the basal ganglia and cortex
• D. Prion protein conformational changes forming
spongiform encephalopathy
CorreCt Answer: A
rAtionAle: The clinical history and MRI findings are
classic for Alzheimer's disease, the most common cause
of dementia in older adults. The primary
histopathological markers are extracellular plaques
composed of amyloid-beta peptides and intracellular
neurofibrillary tangles containing hyperphosphorylated
tau proteins. Alpha-synuclein inclusions characterize
Lewy body dementia; focal vascular infarcts define
vascular dementia; and prion mutations trigger rapidly
progressive Creutzfeldt-Jakob disease.
Q5. A 30-year-old female presents with recurrent
abdominal pain associated with defecation, alternating
diarrhea and constipation, and bloating for the past 9
months, satisfying Rome IV criteria for Irritable Bowel
Syndrome (IBS). Alarm features like weight loss and
